ANPAC Bio-Medical launching new facility in Pennsylvania.
Dr. Shepard shared the 2006 Alpert Prize for his contribution to the development of the breast cancer therapy Herceptin, the first target-directed cancer treatment for solid tumors.
H. Michael Shepard, PhD
Technical Board Consultant

• Founder, president and CSO of Receptor BioLogix, a California-based biopharmaceutical company

• Formerly, he was chief scientific officer and vice president of research at Canji, Inc., where he developed the application of the p53 gene product for cancer treatment.

• Led to the discovery and development of the breast cancer drug, Trastuzumab (herceptin)

• Dr. Shepard shared the 2006 Alpert Prize for his contribution to the development of the breast cancer therapy Herceptin, the first target-directed cancer treatment for solid tumors.